Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Diluted Average) (2021 - 2026)

Rani Therapeutics Holdings' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $180.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 438.27% to $180.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $180.0 million, a 438.27% increase, with the full-year FY2025 number at $66138.0, up 132.26% from a year prior.
  • Shares Outstanding (Diluted Average) came in at $180.0 million for Q1 2026, up from $66138.0 in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $180.0 million in Q1 2026, with the low at $23817.0 in Q4 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $30.6 million across 5 years, with a median of $25.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 3.15% in 2024 and later skyrocketed 438.27% in 2026.
  • Year by year, Shares Outstanding (Diluted Average) stood at $23817.0 in 2022, then grew by 7.09% to $25505.0 in 2023, then grew by 11.65% to $28476.0 in 2024, then surged by 132.26% to $66138.0 in 2025, then surged by 272052.17% to $180.0 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for RANI at $180.0 million in Q1 2026, $66138.0 in Q4 2025, and $46.4 million in Q3 2025.